Toku

Toku is a healthcare technology company that focuses on advanced artificial intelligence applications for preventive health diagnostics through retinal imaging. Founded in 2019 by experts in ophthalmology, Toku has expanded its mission from ocular health to addressing cardiovascular and systemic diseases using eye scans. The company's flagship platform, CLAiR (Cardiovascular Risk AI), analyzes retinal images to detect changes in blood vessels and pigmentation, predicting risks for conditions such as blindness, cardiovascular diseases, and chronic kidney disease. Toku also offers MyKidneyAI, which identifies chronic kidney disease through retinal analysis, and BioAge, a tool that estimates biological age based on retinal images. These platforms are designed for integration into routine eye exams, making early detection of health risks more accessible. Toku serves a variety of healthcare providers, including optometry clinics and primary care offices, with a focus on providing preventive healthcare to underserved populations. The company has relocated its headquarters to San Diego, California, to enhance its presence in the U.S. healthcare market and is committed to delivering equitable healthcare solutions worldwide.

• Employees 20
• Founded 2019
• Annual Revenue $1800000
• Total Funding $13361220